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Stroke has multiple etiologies but the underlying genes and pathways are largely 359 
unknown. We conducted a multi-ancestry genome-wide association meta-analysis in 360 
521,612 individuals (67,162 cases and 454,450 controls) and discovered 22 novel stroke 361 
risk loci bringing the total to 32. We further found shared genetic variation with related 362 
vascular traits including blood pressure, cardiac traits, and venous thromboembolism at 363 
individual loci (N=18), and using genetic risk scores and LD score regression. Several 364 
loci exhibited distinct association and pleiotropy patterns for etiological stroke subtypes. 365 
Eleven novel loci point to mechanisms not previously implicated in stroke 366 
pathophysiology, with prioritization of risk variants and genes accomplished through 367 
bioinformatics analyses using extensive functional datasets. Stroke risk loci were 368 
significantly enriched in drug targets for antithrombotic therapy. 369 
 370 
Stroke is the second leading cause of death and disability-adjusted life-years worldwide.1,2 371 
Characterized by a neurological deficit of sudden onset, stroke is mostly caused by brain 372 
infarction (ischemic stroke) and, less often, intracerebral hemorrhage (ICH). Common 373 
etiological subtypes of ischemic stroke include large artery atherosclerotic stroke (LAS), 374 
cardioembolic stroke (CES), and stroke caused by small vessel disease (small vessel stroke, 375 
SVS), the latter being also the leading cause of ICH. Previous genome-wide association 376 
studies (GWAS) in predominantly European ancestry groups have identified 10 loci robustly 377 
associated with stroke.3-12 In most instances, the association with stroke could be attributed to 378 
individual subtypes of ischemic stroke, such as LAS5,8,9, CES3,4, and SVS10,12 or of ICH6 379 
although some loci were associated with two or more stroke subtypes7,9,11,13 or with any 380 
stroke.10 We hypothesized that combining a substantially enlarged sample size with a 381 
transethnic analytic approach would identify additional risk loci and improve fine mapping of 382 
causal variants. Hence, we combined all available stroke samples with published or 383 
unpublished GWAS data including samples of non-European ancestry that were 384 
underrepresented in previous GWAS. We further hypothesized that stroke shares genetic 385 
influences with vascular risk factors, intermediate phenotypes for stroke (e.g., carotid artery 386 
plaque, cPL), and related phenotypes (e.g., coronary artery disease, CAD) and that a 387 
systematic approach to identify genetic influences shared among these traits would provide 388 
insights into stroke pathophysiology. 389 
  390 
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RESULTS 391 
 392 
We tested ~8 million single nucleotide polymorphisms (SNPs) and InDels with minor allele 393 
frequency (MAF) > 0.01 in up to 67,162 stroke cases and 454,450 controls for association 394 
with stroke. One analysis was of European participants only (40,585 cases; 406,111 controls) 395 
and a second involved participants of European, East-Asian (17,369; 28,195), African (5,541; 396 
15,154), South-Asian (2,437; 6,707), mixed Asian (365; 333), and Latin-American (865; 692) 397 
ancestry (Fig. 1). Participants were drawn from 29 studies with genome-wide genotypes 398 
imputed to 1000 Genomes phase 1v3 or similar14 (The MEGASTROKE consortium, 399 
Supplementary Note, Supplementary Tables 1-2). Ancestry-specific meta-analyses were 400 
conducted followed by fixed-effects transethnic meta-analyses and MANTRA transethnic 401 
meta-analyses.15 Analyses were performed for any stroke, comprising ischemic stroke, ICH, 402 
and stroke of unknown or undetermined type (any stroke, AS, N=67,162), any ischemic 403 
stroke regardless of subtype (AIS, N=60,341) and ischemic stroke subtypes (LAS, N=6,688; 404 
CES, N=9,006; SVS, N=11,710). 405 
 406 
 407 
Genome-wide association results 408 
 409 
New genome-wide significant stroke loci  410 
We identified 32 genome-wide significant loci, 22 of which were novel (Table 1, Fig. 2, 411 
Supplementary Tables 3-4, Supplementary Fig. 1-7). Of the 22 novel loci, 18 were 412 
identified by transethnic meta-analyses (fixed effects p-value < 5.0x10-8 or MANTRA 413 
log10(Bayes factor)[BF] > 6)(Fig. 2 and Supplementary Fig. 1-5) and the remaining 4 were 414 
identified by the ancestry-specific meta-analysis in European samples (fixed effects p < 415 
5.0x10-8) (Fig. 2 and Supplementary Fig. 1-5). Apart from 2 novel loci with a MAF between 416 
0.01 and 0.05 and large effect size estimates (odds ratios [ORs] of 2.33 and 1.95), the 417 
remaining 20 novel loci harbored common variants (MAF 0.16-0.48) with observed ORs 418 
between 1.05 and 1.20 (Table 1). Comparison of the 32 loci across Europeans and East-419 
Asians, the two largest ethnic subgroups, demonstrated significant correlations of risk allele 420 
frequencies and ORs between populations (Supplementary Fig. 8), although 6 loci exhibited 421 
population-specific association (defined as p < 5.0x10-8 in Europeans and p > 0.05 in East-422 
Asians or MAF in East-Asians < 0.01)(Supplementary Table 5). Estimates for the 423 
phenotypic variance explained by the 32 lead variants ranged between 0.6% and 1.8% 424 
(Supplementary Table 6). 425 
Gene-based tests using VEGAS216 (Supplementary Fig. 9) confirmed the loci identified by 426 
the GWAS analyses above, and yielded a novel significant (p < 2.02x10-6, Bonferroni 427 
corrected for the number of genes) association for the neighbouring genes ICA1L and WDR12 428 
with SVS (Supplementary Table 7, Supplementary Fig. 9-10). Prior studies have 429 
demonstrated that variants in this region are associated with white matter hyperintensity 430 
(WMH) burden17 a brain magnetic resonance imaging marker of small vessel disease (SVD).  431 
Twenty-one additional loci met a less stringent threshold for suggestive evidence of 432 
association (log10[BF] > 5.0 or p < 1.0x10-6 in the transethnic fixed effects 433 
analysis)(Supplementary Table 8), among them three loci previously implicated in 434 
Mendelian stroke (HTRA118,19, COL4A120, and COL4A221). 435 
 436 
 437 
 438 
Associations with etiological stroke subtypes 439 
Eighteen loci (12 novel) reached genome-wide significance for AS, 20 (12 novel) for AIS 440 
(20), 6 (3 novel) for LAS, 4 (2 novel) for CES, and 2 (ICA1L-WDR12 novel, discovered in 441 
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gene-based tests) for SVS (Fig. 2, Table 1, Supplementary Fig. 1-5 & 10). Several loci 442 
reaching genome-wide significance for one of the ischemic stroke subtypes were also 443 
genome-wide significant for AIS or AS, while none reached genome-wide significance for 444 
multiple ischemic stroke subtypes (Fig. 2, Supplementary Table 9). For some novel loci, the 445 
association was strictly confined to a single subtype (p > 0.5 for other stroke subtypes): 446 
EDNRA and LINC01492 showed association with LAS only, suggesting mechanisms limited 447 
to atherosclerosis; NKX2-5 showed association with CES only, implying that the association 448 
may be primarily mediated by cardioembolism. We also found subtype-specificity for 449 
previously published loci (TSPAN2 for LAS and PITX2 for CES). We further investigated 450 
shared genetic influences of individual loci on different stroke subtypes using gwas-pw 451 
analyses22, which estimate the posterior probability that a specified genomic region influences 452 
two different traits. Applying a posterior probability cut-off of 90% for shared contribution at 453 
a given locus (model 3) we found shared genetic influence between LAS and SVS at SH2B3, 454 
and between LAS and CES at ABO (Supplementary Table 10 and Supplementary Fig. 11).  455 
 456 
Conditional analysis to identify independent signals within loci 457 
When conditioning all SNPs in a ±0.5 Mb window on the lead SNPs in the Europeans–only 458 
analysis, we found two additional independent genome-wide signals at the PITX2 locus for 459 
CES, consistent with known multiple independent loci at PITX2 for atrial fibrillation (AF),23 460 
suggesting that a similar genetic architecture at this locus influences both conditions 461 
(Supplementary Fig. 12). We further found suggestive independent signals at MMP12, 462 
SH2B3, and HDAC9-TWIST1 that did not reach genome-wide significance (Supplementary 463 
Table 11). 464 
 465 
 466 
Genetic overlap with related vascular traits 467 
 468 
Association of individual stroke risk variants with related vascular traits 469 
Several of our loci are in genomic vicinity of established risk loci for vascular risk factors 470 
(e.g., blood pressure, BP), and related vascular phenotypes affecting the heart (e.g., CAD), 471 
vasculature (e.g., carotid intima media thickness, cIMT), or brain (WMH). To systematically 472 
explore genetic overlap between stroke and these traits we surveyed published GWAS for BP, 473 
blood lipids, type 2 diabetes (T2D), cIMT, cPL, AF, venous thromboembolism (VTE), CAD, 474 
and WMH, assembled through the IGEN-BP24, ENGAGE25, DIAGRAM26, CHARGE27,28, 475 
AFGen29, INVENT30, and CARDIoGRAMplusC4D31 consortia (Supplementary Table 12). 476 
When constructing sets of index SNPs of the non-stroke phenotypes (Bonferroni adjusted p < 477 
1.3x10-4 = 0.05/32 loci/12 related vascular traits) and SNPs in high LD (r2 > 0.9 in 1000G 478 
EUR) with those index variants, 17 of the 32 stroke lead variants showed overlap with these 479 
sets (Supplementary Table 13, Fig. 3). Fourteen loci reached genome-wide significance (p < 480 
5.0x10-8) for association with one or more of the following phenotypes: BP (5 loci), CAD (5 481 
loci), AF (2 loci), VTE (2 loci), LDL-cholesterol (2 loci), cPL (1 locus), and WMH (1 locus). 482 
Among the 21 additional subthreshold loci for stroke (Supplementary Table 8) 6 loci have 483 
previously been associated with related vascular traits including AF (PRRX32, CAV1/232), 484 
VTE (F1130), CAD (SWAP70, LPA31), blood lipids (LPA31), and WMH (ICA1L-WDR1228).  485 
 486 
Association of genetic risk scores of related vascular traits  487 
Second, we generated weighted genetic risk scores (wGRS) for VTE, BP-related traits, blood 488 
lipids, T2D, and CAD using the lead SNPs from published GWAS and tested these wGRS for 489 
association with each stroke phenotype, implementing the inverse-variance weighting  490 
approach (Methods, Supplementary Table 14). We found significant associations (p < 491 
5.6x10-3 correcting for 9 independent phenotypes, see Methods) with wGRS for all traits 492 
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examined, except for triglyceride and LDL-cholesterol levels, with clear differences between 493 
stroke subtypes (Fig. 4). The strongest association was between the wGRS for CAD and LAS 494 
consistent with shared pathophysiology through atherosclerosis. We further found 495 
associations of all stroke subtypes with wGRS for BP traits. The wGRS for VTE was 496 
significantly associated with both LAS and CES (all p < 1.0x10-4) but not SVS. The wGRS 497 
for HDL-cholesterol showed a significant inverse association with SVS.  498 
In the present setting the wGRS analysis was used primarily to explore the genetic overlap 499 
with related vascular traits, not as a tool for establishing causal inference. In sensitivity 500 
analyses we conducted an MR-Egger regression to explore whether any of the significant 501 
associations between vascular wGRS and stroke may be partly driven by directional 502 
pleiotropy. There was no indication of directional pleiotropy except for the association 503 
between the SBP wGRS and AS (MR-Egger intercept estimate p=0.015), which was no 504 
longer significant after removing 6 of 37 SNPs appearing as outliers from the leave-one-out 505 
analysis (Methods), leading to causal estimates in broad agreement across regression 506 
techniques (Supplementary Table 15).   507 
 508 
Shared genetic contribution to stroke and related vascular traits at the whole genome 509 
level 510 
Third, we applied LD score regression to quantify the extent of shared genetic contributions 511 
between traits on a whole genome level.33,34 Using available GWAS results from individuals 512 
of European ancestry, we found significant positive correlations (rg > 0; p < 5.6x10-3 513 
correcting for 9 independent phenotypes), mostly corroborating the wGRS results (Fig. 4 and 514 
Supplementary Table 16). In addition, we found significant genetic overlap between 515 
triglyceride levels and AIS with similar results obtained in available GWAS datasets from 516 
East-Asian ancestry (Supplementary Table 16). Results did not materially change when 517 
removing genome-wide signals for stroke and related vascular traits and their proxies (r2 >0.8 518 
in 1000G EUR). 519 
 520 
 521 
Global functional interpretation of stroke risk loci 522 
 523 
Global epigenetic patterns at the 32 stroke risk loci 524 
To test for cell-specific enrichment in chromatin marks that were previously shown to be 525 
phenotypically cell-type specific in ENCODE/RoadMap (H3K4me1, H3K4me3, H3K9ac)35, 526 
we implemented the epigwas tool35 and the narrow peak information from the latest RoadMap 527 
dataset (127 tissues).36 Epigwas estimates the enrichment score (ratio of the height of the 528 
nearest narrow peak over the distance to the peak) for the lead variant and proxies (r2 >0.8 in 529 
1000G cosmopolitan panel) and calculates statistical significance by examining the relative 530 
proximity and specificity of the test SNP-set with 10,000 sets of matched background. The 531 
analysis showed significant enrichment of enhancer and promoter sites (H3K4me1, 532 
H3K4me3) in mesenchymal stem cells, embryonic stem cells, epithelial cells, and blood & T-533 
cells, and of active promoters (H3K9ac) in embryonic stem cells and digestive tissue 534 
(Supplementary Table 17). 535 
 536 
Pathway Analyses  537 
To identify pathways overrepresented in stroke association results we used the DEPICT gene-538 
set enrichment tool37 using all SNPs with log10(BF) > 5 for the respective stroke subtype. We 539 
found three gene-sets to be significantly (FDR < 5%) associated with AS: enlarged heart, 540 
decreased cardiac muscle contractility, and oxaloacetate metabolic process (Supplementary 541 
Table 18). Next, we used Ingenuity Pathway Analysis 542 
(https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/) examining 543 
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genes within the 53 stroke locwith log10(BF) > 5. The extended gene list (r2 > 0.5 in 1000G 544 
Europeans or East-Asians, or located within 50kB of the lead SNP) consisted of 214 genes. 545 
We found the coagulation system to be the most significant canonical pathway followed by 546 
cardiomyocyte differentiation via bone morphogenetic protein receptors (FDR 5%) 547 
(Supplementary Table 19). Finally, we tested enrichment of VEGAS2 derived gene-based p-548 
values in expert curated and computationally predicted Biosystem gene-sets38 adapting 549 
VEGAS2Pathway,39 and identified significant association with 18 pathways including various 550 
cardiac pathways, muscle cell fate commitment, and nitric oxide metabolic process with CES 551 
(FDR 5%) (Supplementary Table 20). 552 
 553 
 554 
Prioritizing potential causal variants  555 
 556 
Fine-mapping derived from credible SNP set analyses 557 
To reduce the number of candidate variants per locus to the most noteworthy associations we 558 
constructed 95% credible SNP sets for each of the 32 loci (lead SNP and proxy SNPs r2 > 0.1 559 
in 1000G panels) assuming one causal SNP per locus and uniform priors.40 Credible SNP sets 560 
were generated in all stroke phenotypes and for European, East-Asian, and African ancestries 561 
separately. We found a marked reduction of credible SNP sets for most loci, expectedly most 562 
pronounced for the phenotype showing the strongest association signal (Supplementary 563 
Table 21). The greatest refinement was observed at RGS7, HDAC9-TWIST1, and SH2B3, 564 
where the lead SNP was the only SNP contained in the 95% credible set for the stroke 565 
phenotype showing the strongest association.  566 
 567 
Stroke loci with nonsynonymous or predicted deleterious variants 568 
To determine SNPs that have protein-altering effects, we annotated all SNPs using 569 
ANNOVAR.41 Of the 32 lead SNPs three were exonic, of which two were non-synonymous 570 
(rs3184504 [p.Arg262Trp] in SH2B3 and rs1052053 [p.Gln75Arg] in PMF1). p.Arg262Trp is 571 
a loss-of function variant that leads to expansion of hematopoetic stem cells and enhanced 572 
megakaryopoiesis in humans.42 Both variants are predicted to be benign or tolerated by 573 
PolyPhen43 and SIFT.44 In addition, we identified a proxy SNP (r2=0.99 in 1000G EUR) for 574 
another lead SNP, that was non-synonymous (rs6050 [p.Thr331Ala] in FGA), also predicted 575 
as benign or tolerated. 576 
 577 
Investigation of eQTLs, meQTLs, and pQTLs in different tissues 578 
We interrogated genome-wide gene expression (expression quantitative trait loci, eQTLs), 579 
methylation (meQTLs), and protein expression (pQTLs) in extensive publicly and non-580 
publicly available datasets to determine whether stroke risk SNPs influenced the 581 
cis regulation of nearby genes. These datasets encompass numerous tissues and cell types 582 
including cardiac, vascular, and brain tissue, circulating cells, and vascular endothelial cells 583 
(Methods). These comprise: for eQTLs the GTEx V645, an expanded version of GRASP246,47, 584 
HGVD48, BIOS49, Blueprint epigenome project (subset)50, STARNET51 and the human aortic 585 
endothelial cells study52; for meQTLs, the Blueprint epigenome project (subset)50 and the 586 
ARIC cohort53, and for pQTLs the KORA cohort.54 Only cis eQTLs, meQTLs, and pQTLs 587 
were considered.     588 
We found that in 18 of the 32 stroke risk loci the lead stroke risk variant either overlapped or 589 
was in moderate to high LD (r2>0.8) with the most significant QTL variant for a nearby gene, 590 
in at least one tissue or cell type (Supplementary Table 22 and 23). For seven loci, we 591 
observed association of the lead SNP and proxies with expression of a single gene (or 592 
methylation or protein level), sometimes the nearest gene (LRCH1, CDK6, CDKN2B, PRPF8, 593 
and MMP12), sometimes a more distant nearby gene (ZCCHC14 for the ZCCHC14 locus, and 594 
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TWIST1 for the HDAC9-TWIST1 locus), within the datasets we explored. Associations were 595 
mostly found in stroke-relevant tissues and cell types, including vascular tissues, aortic 596 
endothelial cells, brain, blood, and immune cells. In most instances (11 loci, 61.1%), the risk 597 
SNP affected expression of multiple genes suggesting that at individual loci pleiotropic 598 
mechanisms, which might differ according to tissue/cell type, could in some instances 599 
influence stroke susceptibility.55,56 For several of these loci there was a clear predominance of 600 
eQTL associations with one gene in stroke-relevant tissues, such as ZNF318 (chr6p21), 601 
AL049919 (chr12q24), and FES (chr15q26) in brain tissues (Supplementary Table 22-23).  602 
At some loci, meQTLs and eQTLs provided complementary information on the regulatory 603 
pattern. For instance, for the SH3PXD2A locus, SNPs in high LD with the lead stroke risk 604 
variant are eQTLs for multiple genes (SH3PXD2A, SLK, GSTO1, GSTO2, LOC729081), 605 
while several high LD proxies (r2>0.96) function as the most significant meQTL for CpG 606 
probes located in the promoter region of SH3PXD2A and not any of the other genes.   607 
For the 149 genes located in the 32 genome-wide significant loci (r2 > 0.5 in Europeans or 608 
East-Asians, or being located +50kB from the lead SNP, Methods), we assigned an empirical 609 
functional score based on the presence and number of eQTLs, meQTLs, pQTLs and other 610 
biological criteria57,58 (Methods and Supplementary Table 24) reasoning that genes with a 611 
higher functional score are more likely to be causal, although this score requires validation by 612 
experimental data. 613 
 614 
Joint modeling of epigenetic marks and association statistics  615 
As an additional approach to identify the most plausible causal variants and genes we used 616 
RiVIERA59, which jointly models summary association statistics and corresponding 617 
epigenetic regulatory information in a Bayesian framework to estimate the posterior 618 
probability of association (PPA). RiVIERA uses the RoadMap epigenome data of 127 tissue 619 
types and information on chromatin (H3K4me1, H3K4me3, H3K36me3, H3K27me3, 620 
H3K9me3, H3K27ac, H3K9ac), and DNA accessibility (DNaseI) marks. Three of the stroke 621 
risk loci (PMF1-SEMA4A, SH3PXD2A, and EDNRA) displayed a pattern in which the 622 
association statistics and epigenetic regulatory information jointly contributed to the modeling 623 
of the RiVIERA credible SNP set (the minimum number of SNPs whose PPA, accounting for 624 
both association statistics and epigenetic regulatory information, sum up to 625 
>95%)(Supplementary Fig. 13). The variants identified by RiVIERA as having the highest 626 
PPA were in moderate to high LD in the 1000G cosmopolitan panel with the respective lead 627 
SNP (rs7534434 for PMF1- SEMA4A [r2=0.79 with lead SNP]; rs11191829 for SH3PXD2A 628 
[r2=0.99]; rs4835084 for EDNRA [r2=0.35]). Two of these (at PMF1- SEMA4A and 629 
SH3PXD2A) were significantly enriched for RNA Pol II binding in ENCODE cell types60 630 
including H1-hESC (human embryonic stem cells) (Supplementary Fig. 13).  631 
 632 
Enrichment in drug target genes 633 
Given previous evidence for utility of GWAS for drug discovery and drug repositioning57,61,62 634 
we evaluated the overlap between stroke-associated genes and known drug targets. Among 635 
the 149 genes located within the 32 stroke risk loci, 16 (11%) were registered as targets of 636 
currently approved drugs in the DrugBank database and the Therapeutic Target Database 637 
(Supplementary Table 25). Of these, two genes (FGA, PDE3A) were targets of approved 638 
drugs for antithrombotic therapy (ATC B01), i.e. alteplase, tenecteplase, reteplase and 639 
anistreplase for FGA, and cilostazol for PDE3A (enrichment OR=5.46, p=0.0369; Fig. 5). 640 
This enrichment was strengthened after removing the locus with the largest number of genes 641 
(SH2B3, 73 genes) (OR=8.89, p=0.0166) and after adding 65 genes in 21 suggestive stroke 642 
risk loci (OR=7.83, p=0.00606).  643 
 644 
 645 
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DISCUSSION 646 
 647 
The current transethnic meta-analysis more than triples the number of stroke risk loci and 648 
identifies novel loci for AS, AIS, and all major subtypes of ischemic stroke. Our results 649 
highlight several major features of stroke genomics: (i) approximately half of the identified 650 
stroke loci show shared genetic association with other vascular traits, the largest genetic 651 
correlation being found for BP. We also identified shared genetic association with VTE, with 652 
distinct patterns for individual stroke subtypes providing mechanistic insight; (ii) eleven of 653 
the novel stroke loci (ANK2, CDK6, KCNK3, LINC01492, LRCH1, NKX2-5, PDE3A, PRPF8, 654 
RGS7, TM4SF4-TM4SF1 and WNT2B) point to mechanisms not previously implicated in 655 
stroke pathophysiology; some of these suggest a strong link with cardiac mechanisms beyond 656 
those expected from established sources of cardioembolism; (iii) the 32 stroke risk loci were 657 
significantly enriched in drug targets for antithrombotic therapy, one for an approved 658 
thrombolytic drug (alteplase) and the other for an antiplatelet agent (cilostazol) approved for 659 
stroke prevention in Asia; (iv) through incorporation of extensive functional datasets and 660 
bioinformatics analyses we provide detailed information on prioritization of stroke risk 661 
variants and genes as a resource for further experimental follow-up.  662 
The majority of genome-wide associations were identified with both AS and AIS. While this 663 
relates in part to a higher power compared to subtypes, we also found shared genetic 664 
influences between stroke subtypes, as exemplified by the gwas-pw analyses (SH2B3 and 665 
ABO). A notable finding is the identification of PMF1-SEMA4A as a risk locus for AIS. 666 
PMF1-SEMA4A is an established risk locus for non-lobar ICH6 and thus represents the first 667 
locus reaching genome-wide significance for ischemic as well as hemorrhagic stroke. PMF1-668 
SEMA4A further reached genome-wide association for WMH burden28 (Fig. 3), an established 669 
marker for SVD, and showed a strong signal in the SVS subtype suggesting that the 670 
association with stroke is at least in part mediated by SVD. The underlying biological 671 
pathways do not seem to involve known vascular risk factors and may thus reveal novel 672 
targets for stroke prevention.  673 
Among the novel loci showing associations restricted to specific stroke subtypes, EDNRA is 674 
consistent with atherosclerotic mechanisms given its association with LAS, cPL27 and CAD31 675 
(Fig. 3). LINC01492 and the previously reported TSPAN2 locus likewise displayed 676 
associations restricted to LAS but showed no association with related phenotypes in our look-677 
ups and in prior literature, thus evidencing mechanisms more specific for LAS. NKX2-5, 678 
showing association restricted to CES, was previously reported as a genome-wide risk locus 679 
for heart rate and PR interval63,64 but not consistently for AF63,65 thus pointing towards cardiac 680 
mechanisms other than AF. 681 
 682 
Although the number of loci reaching genome-wide significance for association with SVS 683 
remains low, our results suggest an important role for common genetic variation in SVS. First, 684 
several of the associations with AS or AIS including at novel loci (CASZ1, LOC100505841, 685 
SH3PXD2A, ICA1L-WDR12) show predominant association with the SVS subtype 686 
(Supplementary Table 7 and Supplementary Table 9). Second, three of the top loci 687 
(PMF1-SEMA4A, LOC100505841, SH3PXD2A) show genetic overlap with loci for WMH. 688 
Third, several suggestive loci (log10[BF] >5) for AS and SVS harbor genes implicated in 689 
monogenic SVD (HTRA1, COL4A1, COL4A2) (Supplementary Table 8). 690 
Our extensive exploration of shared genetic variation between stroke and related vascular 691 
traits found the most widespread correlations with BP phenotypes consistent with 692 
epidemiological data showing high BP to be the leading risk factor for stroke. A quarter of the 693 
32 genome-wide significant stroke loci are BP loci, most of which are novel with respect to 694 
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stroke risk and show association with risk of AS or AIS. Aside from expected genetic overlap 695 
between LAS and CAD, we also identified significant overlap between a wGRS for VTE and 696 
both LAS, and CES, but not SVS (Supplementary Table 14, Fig. 4) despite a higher power 697 
for this subtype, potentially suggesting that thrombotic processes play a less important role in 698 
SVS. 699 
Three of our novel loci (NKX2-5, ANK2, and LRCH1) have previously been associated with 700 
cardiac pacing.63,64,66 NKX2-5 and ANK2 are further implicated in familial forms of cardiac 701 
disease67-70 but none of the three loci was associated with AF or CAD in the latest published 702 
GWAS.31,65 Apart from NKX2-5 they were not specifically associated with CES, possibly 703 
pointing to an involvement of the underlying genes beyond cardiac development and function. 704 
rs9526212, the lead variant in LRCH1 functions as an eQTL for LRCH1 in multiple tissues 705 
including left ventricle, atherosclerotic aorta, atherosclerotic-lesion free arteries, and blood 706 
(Supplementary Table 22). Pathway analyses further support a strong link with cardiac 707 
mechanisms.  708 
 709 
The extensive in silico functional annotation of identified stroke risk loci provides informative 710 
elements for future prioritization and follow-up of the most compelling biological candidates. 711 
In some instances, the eQTL, meQTL and pQTL information strongly supports involvement 712 
of one gene over others in the region, e.g., for SH3PXD2A, encoding SH3 and PX domain-713 
containing protein 2A, an adapter protein involved in invadopodia and podosome formation as 714 
well as extracellular matrix degradation. For some loci, joint analysis of epigenetic regulatory 715 
effects and association statistics enabled prioritization of credible SNPs. When exploring 716 
overall epigenetic patterns of identified stroke risk loci, some enrichment of enhancer and 717 
promoter sites in developmental tissues was observed, suggesting that some associations may 718 
be driven by developmental effects, as recently proposed for the FOXF2 locus.10 719 
  720 
RGS7 and TM4SF4-TM4SF1 showed low minor allele frequencies, high heterogeneity, poor 721 
imputation quality in non-Europeans, and large effect size estimates and must therefore be 722 
interpreted with caution. Moreover, while our extensive functional exploration provides 723 
guidance on gene prioritization for further exploration, additional experiments are required to 724 
identify the causal genes and variants. Several studies had limited information on stroke 725 
subtypes. Hence sample sizes for ischemic stroke subtypes were still in the lower range. Also, 726 
the proportion of the phenotypic variance explained by the 32 lead SNPs was relatively small 727 
but comparable to other complex diseases.71 Collectively, these aspects highlight the potential 728 
for gene discovery in the future. 729 
 730 
In conclusion, we identify 22 novel stroke risk loci and demonstrate shared genetic variation 731 
with multiple related vascular traits. We further identify novel loci offering mechanisms not 732 
previously implicated in stroke pathophysiology and provide a framework for prioritization of 733 
stroke risk variants and genes for further functional and experimental follow-up. Stroke risk 734 
loci are significantly enriched in drug targets for antithrombotic therapy thus highlighting the 735 
potential of stroke genetics for drug discovery. Collectively, these findings represent a major 736 
advance in understanding the genetic underpinnings of stroke. 737 
  738 
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FIGURE LEGENDS 1113 
 1114 
Figure 1 MEGASTROKE study design. Variants were retained that passed central QC 1115 
criteria (Methods). Number of cases / number of controls are listed for each ancestry. 1000G, 1116 
1000 Genomes; HRC, Haplotype reference consortium; MAF, minor allele frequency; rsq, 1117 
squared correlation between imputed and true genotypes; imp, measure of imputation quality 1118 
(Methods); FE, fixed-effects; EUR, European ancestry; AFR African ancestry; EAS, East 1119 
Asian ancestry; SAS, South Asian ancestry; ASN, mixed Asian ancestries; LAT, Latin 1120 
American ancestry. Phet, heterogeneity p-value; PPhet, posterior probability of heterogeneity. * 1121 
Note the ASN and LAT ancestries were composed of a single study so did not require 1122 
ancestry specific meta-analysis. 1123 
 1124 
Figure 2 Association results of the transethnic GWAS meta-analysis and the prespecified 1125 
ancestry-specific meta-analysis in European samples. Shown are novel (red) and replicated 1126 
(black) genetic loci associated with any stroke or stroke subtypes. The upper panel displays 1127 
the Manhattan plot from the MANTRA transethnic GWAS meta-analysis for any stroke. The 1128 
dotted line marks the threshold of statistical significance (log10(Bayes factor) > 6.0). 1129 
 1130 
Figure 3 Genetic overlap between stroke and related vascular traits at the 32 genome-wide 1131 
significant loci for stroke. (A) Association results from the look-ups in published GWAS data 1132 
for related vascular traits. Symbol sizes reflect p-values for association with the related trait. 1133 
(B) Venn diagram. Loci reaching genome-wide significance for association with stroke 1134 
subtypes are marked by a dagger symbol (for CES), underlined (for LAS), or marked by an 1135 
asterisk (for SVS). Novel loci are in bold. Note that SH3PXD2A, WNT2B, PDE3A and 1136 
OBFC1 have previously been associated with AF (SH3PXD2A)65, DBP (WNT2B and 1137 
PDE3A)24,88 or SBP (OBFC1)89, but the respective lead SNPs were in low LD (r2<0.1 in 1138 
1000G cosmopolitan panel) with variants associated with stroke in the current GWAS. MRI, 1139 
magnetic resonance imaging; CAD, coronary artery disease; IMT, intima-media thickness. 1140 
BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein. Note that 1141 
the lead variant for TBX3 is not included in the original data sets for BP traits (SBP and 1142 
DBP). Results are based on a perfect proxy SNP (rs35432, r2=1 in the European 1000G phase 1143 
3 reference). 1144 
 1145 
Figure 4 Shared genetic contribution between stroke and related vascular traits as determined 1146 
by weighted genetic risk scores (wGRS, upper panel) and LD score regression analysis (lower 1147 
panel). Effect sizes and significance levels are represented by color and symbol size. β, wGRS 1148 
effect size; R(g), genetic correlation.Sample sizes for related vascular traits are displayed in 1149 
Supplementary Table 12. 1150 
 1151 
Figure 5 Connection between stroke risk genes and approved drugs for antithrombotic 1152 
therapy. Shown are the connections between lead SNPs at stroke risk loci, biological stroke 1153 
risk genes, and individual targeted drugs. Lead SNPs reaching suggestive evidence for 1154 
association (MANTRA transethnic meta-analysis log10(Bayes factor) > 5) are shown in grey. 1155 
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rsID Chr Gene(s) Location relative to gene 
Risk allele/ 
reference allele 
Risk allele 
frequency, 
% 
Phenotype Analysis OR 95% CI P-value log10 (BF) 
  Novel associations  
rs880315 1p36 CASZ1 Intronic C/T 40 AS TRANS 1.05 1.04-1.07 3.62E-10 8.09 
rs12037987 1p13 WNT2B Intronic C/T 16 AS TRANS 1.07 1.05-1.10 2.73E-08 6.33 
rs146390073 1q43 RGS7 Intronic T/C 2 CES EUR 1.95 1.54-2.47 2.20E-08 NA* 
rs12476527 2p23 KCNK3 5’-UTR G/T 48 AS TRANS 1.05 1.03-1.07 6.44E-08 6.47 
rs7610618 3q25 TM4SF4-TM4SF1 Intergenic T/C 1 LAS EUR 2.33 1.74-3.12 1.44E-08 NA** 
rs34311906 4q25 ANK2 Intergenic C/T 41 AIS EUR 1.07 1.04-1.09 1.07E-08 5.67 
rs17612742 4q31 EDNRA Intronic C/T 21 LAS TRANS 1.19 1.13-1.26 1.46E-11 9.47 
rs6825454 4q31 FGA Intergenic C/T 31 AIS TRANS 1.06 1.04-1.08 7.43E-10 7.53 
rs11957829 5q23 LOC100505841 Intronic A/G 82 AIS TRANS 1.07 1.05-1.10 7.51E-09 6.67 
rs6891174 5q35 NKX2-5 Intergenic A/G 35 CES TRANS 1.11 1.07-1.16 5.82E-09 6.96 
rs16896398 6p21 SLC22A7-ZNF318 Intergenic T/A 34 AS TRANS 1.05 1.03-1.07 1.30E-08 6.60 
rs42039 7q21 CDK6 3’-UTR C/T 77 AIS TRANS 1.07 1.04-1.09 6.55E-09 6.84 
rs7859727 9p21 Chr9p21 ncRNA_intronic T/C 53 AS TRANS 1.05 1.03-1.07 4.22E-10 8.01 
rs10820405 9q31 LINC01492 ncRNA_intronic G/A 82 LAS EUR 1.20 1.12-1.28 4.51E-08 4.74 
rs2295786 10q24 SH3PXD2A Intergenic A/T 60 AS TRANS 1.05 1.04-1.07 1.80E-10 8.34 
rs7304841 12p12 PDE3A Intronic A/C 59 AIS TRANS 1.05 1.03-1.07 4.93E-08 5.87 
rs35436 12q24 TBX3 Intergenic C/T 62 AS TRANS 1.05 1.03-1.06 2.87E-08 6.29 
rs9526212 13q14 LRCH1 Intronic G/A 76 AS TRANS 1.06 1.04-1.08 5.03E-10 7.97 
rs4932370 15q26 FURIN-FES Intergenic A/G 33 AIS TRANS 1.05 1.03-1.07 2.88E-08 6.05 
rs11867415 17p13 PRPF8 Intronic G/A 18 AIS TRANS 1.09 1.06-1.13 4.81E-08 6.06 
rs2229383 19p13 ILF3-SLC44A2 Exonic; synon T/G 65 AIS TRANS 1.05 1.03-1.07 4.72E-08 6.02 
rs8103309 19p13 SMARCA4-LDLR Intergenic T/C 65 AS TRANS 1.05 1.03-1.07 3.40E-08 5.85 
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  Previously known associations  
rs12124533 1p13 TSPAN2 Intergenic T/C 24 LAS TRANS 1.17 1.11-1.23 1.22E-08 6.60 
rs1052053 1q22 PMF1-SEMA4A Exonic; nonsyn G/A 40 AS TRANS 1.06 1.05-1.08 2.70E-14 11.92 
rs13143308 4q25 PITX2 Intergenic T/G 28 CES TRANS 1.32 1.27-1.37 1.86E-47 45.10 
rs4959130 6p25 FOXF2 Intergenic A/G 14 AS TRANS 1.08 1.05-1.11 1.42E-09 7.52 
rs2107595 7p21 HDAC9-TWIST1 Intergenic A/G 24 LAS TRANS 1.21 1.15-1.26 3.65E-15 12.99 
rs635634 9q34 ABO Intergenic T/C 19 AIS EUR 1.08 1.05-1.11 9.18E-09 4.99 
rs2005108 11q22 MMP12 Intergenic T/C 12 AIS TRANS 1.08 1.05-1.11 3.33E-08 6.12 
rs3184504 12q24 SH2B3 Exonic; nonsyn T/C 45 AIS TRANS 1.08 1.06-1.10 2.17E-14 12.04 
rs12932445 16q22 ZFHX3 Intronic C/T 21 CES TRANS 1.20 1.15-1.25 6.86E-18 15.49 
rs12445022 16q24 ZCCHC14 Intergenic A/G 31 AS TRANS 1.06 1.04-1.08 1.05E-10 8.57 
Table 1 Results from the transethnic and fixed effects (transethnic and Europeans-only) GWAS meta-analyses. For each locus the variant reaching the highest BF in the MANTRA or the 1156 
lowest p-value in the fixed effects transethnic meta-analysis or the fixed effects Europeans-only meta-analysis, respectively, is shown and the respective stroke phenotype showing the 1157 
strongest association is specified. Gene names in bold indicate that the variant is located within the gene; in other cases the first gene corresponds to the closest gene, whereas additional 1158 
gene names indicate eQTL signals from multiple studies, or from both eQTLs and meQTLs, or genes previously suspected to be causal (LDLR) with a maximum of two genes reported. 1159 
Note that the lead SNPs in ILF3-SLC44A2 and SMARCA-LDLR are in low LD (r2=0.082). Chr, chromosome; TRANS, MANTRA transethnic meta-analysis; EUR, Europeans-only fixed-1160 
effects meta-analysis; OR, odds ratio; CI, confidence interval; BF, Bayes factor; NA, not assessed; * rs146390073 did not meet the MAF threshold of 0.01 in samples other than those of 1161 
European ancestry; **rs7610618: The trans-ethnic meta-analysis results showed high heterogeneity (PPhet=0.96) and were thus excluded1162 
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 1163 
 1164 
ONLINE METHODS 1165 
 1166 
Study design and phenotyping  1167 
A detailed description of the study design, participating studies, and phenotype definitions for 1168 
stroke and stroke subtypes is provided in the Supplementary Note. Characteristics of study 1169 
participants are given in Supplementary Table 2 for each study. All participants provided 1170 
written informed consent, and local research ethics committees and institutional review 1171 
boards approved the individual studies. 1172 
 1173 
Genotyping, imputation and quality control 1174 
Genotyping platforms and imputation methods for each participating study are described in 1175 
Supplementary Table 2. All studies used imputed genotypes based on at least the 1176 
1000Genomes phase 1 multiethnic reference panel and conducted logistic regression analyses 1177 
(or Cox regression for longitudinal population-based cohort studies) for five stroke traits (AS, 1178 
AIS, LAS, CES and SVS) with all measured and imputed genetic variants in dosage format 1179 
using appropriate software under an additive genetic model with a minimum of sex and age as 1180 
covariates. Information on additional covariates is given in Supplementary Table 2. 1181 
Before ancestry-specific meta-analysis, quality control (QC) was performed on each study by 1182 
two independent researchers following a standardized protocol based on the suggestions of 1183 
Winkler et al.72 Marker names and alleles were harmonized across studies. Meta-analyses 1184 
were restricted to autosomal biallelic markers from the 1000Genomes phase1 v3. Duplicate 1185 
markers were removed from each study. P-Z plots, QQ-plots and allele-frequency-plots were 1186 
constructed for each study. After visual inspection, analysis and QC was repeated if deemed 1187 
necessary. QC was conducted independently for all participating studies in at least two sites. 1188 
Individual study-level filters were set to remove extreme effect values (beta > 5 or beta < -5), 1189 
rare SNPs (MAF < 0.01) and variants with low imputation accuracy (oevar_imp or info score 1190 
< 0.5). Effective allele count was defined as twice the product of minor allele frequency, 1191 
imputation accuracy (r2, info score ore oevar_imp), and number of cases. Variants with an 1192 
effective allele count < 10 were excluded.72 The number of SNPs passing QC for each study 1193 
is given in Supplementary Table 26. 1194 
 1195 
Genome-wide Association Meta-Analyses  1196 
The overall analytical strategy is shown in Figure 1. We conducted fixed effects inverse 1197 
variance weighted meta-analysis with METAL73, first in each ethnic group (EUR, EAS, AFR, 1198 
SAS, LAT, and other ASN), followed by meta-analysis of ancestry-specific meta-analysis 1199 
results. We constructed two versions of each meta-analysis: one with single genomic control 1200 
(GC) applied and one without GC (for LD score regression analysis).  1201 
The EUR specific and transethnic fixed effects meta-analysis were further filtered for 1202 
heterogeneity (p_het < 5.0 x 10-8) and for the number of cases included for a specific marker. 1203 
(< 50% of stroke cases were excluded). In addition, we ran a transethnic GWAS meta-1204 
analysis using MANTRA.15 The latter was based on ancestry-specific meta-analysis results. 1205 
Final MANTRA results were filtered for a MANTRA posterior probability heterogeneity p-1206 
value < 0.95. SNPs with log10(BF) > 6 were considered to be genome-wide significant, 1207 
whereas SNPs with 6 > log10(BF) > 5 were considered to show suggestive association. We 1208 
used a method based on summary statistics74 to estimate the variance in liability explained by 1209 
each lead variant. Disease prevalence was set to 5.5% for AS, to 4.4% for AIS and to 0.11% 1210 
for IS subtype in Europeans.75 Disease prevalence was set to 2.97% for AIS, to 0.91% for 1211 
LAS, to 0.24% for CES and to 1.76% for SVS in East-Asians (unpublished data from the 1212 
Hisayama study). We used summary statistics from the Europeans-only fixed-effects meta-1213 
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analysis and the East-Asian-only fixed-effects meta-analysis. Genomic inflation was 1214 
calculated as lambda, using the GenABEL package (available through CRAN repositories). In 1215 
addition, we calculated the LD score regression intercepts for the Europeans-only fixed 1216 
effects meta-analysis using European LD scores. 1217 
 1218 
Shared genetic influences of individual loci on mechanistically defined stroke subtypes 1219 
We used gwas-pw22 to detect shared genetic influences of LAS, CES and SVS, aiming to 1220 
identify genetic variants that influence respective pairs of these traits. Gwas-pw estimates the 1221 
posterior probability (PPA) for four models. Model 3 is the model where a given genomic 1222 
region contains a genetic variant that influences both traits. We used the fixed-effects 1223 
transethnic meta-analysis results as input, transforming results into signed Z scores based on 1224 
p-value and sign of the log(OR). Chunk size (number of SNPs included in each chunk 1225 
analyzed) was set automatically using an approximately independent block file (ld-select) as 1226 
provided by the software. Correlation was set to reflect the overlap in controls. We deemed 1227 
results of model 3 with a PPA > 0.9 as significant.22 1228 
 1229 
Conditional analysis 1230 
We used GCTA-COJO76 to perform conditional association analysis in each of the stroke loci 1231 
in Europeans. We first fit a step-wise joint regression model including all SNPs with joint p-1232 
values < 5.0 x 10-8. In instances where regions included only one SNP, we fit a model 1233 
including the top 2 SNPs from each region. The models made use of (i) summary statistics 1234 
from the Europeans-only meta-analysis presented herein and (ii) genotype data for 3,291 1235 
stroke cases and 11,820 controls of North European ancestry from NINDS-SIGN as an LD-1236 
reference for each region. 1237 
 1238 
Gene-based analysis 1239 
We performed gene-based tests using the VEGAS approach77 implemented in the VEGAS2 1240 
software.16 We used 24,769 autosomal refseq genes to perform gene-based association 1241 
studies. We used 1000 genomes phase 3 super populations African (AFR), East-Asian (EAS), 1242 
European (EUR), American (AMR) and South-Asian (SAS) as a reference to compute pair-1243 
wise LD between variants residing within a gene to perform gene-based association tests. We 1244 
performed gene-based tests using ‘-top 10’ parameter in VEGAS2, which tests enrichment of 1245 
top 10% of association p-values within a gene. To maintain specificity whilst including cis-1246 
regulatory variants, we included variants that are located within 10kb of a gene’s 3’ and 5’ 1247 
untranslated region (UTR). We performed 1 x 106 simulations to compute empirical p-values 1248 
association with each gene. For genes with p-value less than 1 x 10-5 we increased the number 1249 
of simulations to 1 x 108 to increase the accuracy of the association p-values. For individual 1250 
stroke subtypes, we performed ancestry-specific gene-based association followed by meta-1251 
analysis of gene association p-values using Stouffer’s method, based on sample size. 1252 
 1253 
Association of individual stroke risk variants with related vascular traits 1254 
We systematically explored genetic overlap with AF, CAD, cIMT, cPL, diastolic BP, systolic 1255 
BP, HDL-cholesterol levels, LDL-cholesterol levels, triglyceride levels, T2D, VTE and 1256 
WMH. First, we acquired summary statistics from the appropriate consortia (Supplementary 1257 
Table 12). For each of the non-stroke phenotypes we constructed a SNP set including the 1258 
index variant of the non-stroke phenotype with p-value < 1.3 x 10-4 plus all variants in high 1259 
LD (r2 in 1000G EUR > 0.9 with this index variant). If the MEGASTROKE lead SNP was 1260 
included in this set of SNPs we deemed the overlap with the non-stroke phenotype to be 1261 
significant. We show two different tiers: i) variants that showed genome-wide significance in 1262 
the related vascular trait (p <5.0 x 10-8) and ii) variants that were not genome-wide significant 1263 
but passed Bonferroni correction (p=1.3 x 10-4). 1264 
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 1265 
Association of genetic risk scores of related vascular traits with stroke and stroke subtypes 1266 
Genetic risk scores generated from variants that are shown to be genome-wide associated with 1267 
various vascular risk factors (VTE, DBP, SBP, mean arterial pressure [MAP], pulse pressure 1268 
[PP], HTN, HDL-cholesterol, LDL-cholesterol, TG, T2D, CAD) were used to estimate the 1269 
overlap between vascular traits and stroke and its subtypes. The effect allele for each risk 1270 
factor variant was defined as the allele associated with increase in the risk factor levels. 1271 
Corresponding allele information, beta-coefficient and the standard error from different stroke 1272 
subtypes was extracted and used as input. Association was tested using the inverse-variance 1273 
weighting (IVW) method implemented as an R package “gtx V 0.0.8” (available through 1274 
CRAN repositories). 1275 
We further conducted a sensitivity analyses using the MR-Egger method implemented as an R 1276 
package (TwoSampleMR, available through CRAN repositories),78 which unlike the IVW 1277 
method estimates the intercept term as part of the analysis. An intercept term significantly 1278 
differing from zero suggests the presence of directional pleiotropy. We used a conservative 1279 
significance threshold of p<0.05 for the intercept. In the presence of directional pleiotropy, 1280 
leave-one-out analysis was carried out by re-testing the association of the vascular GRS with 1281 
the outcome (stroke) leaving out each SNP in turn, to determine whether a single SNP is 1282 
driving the association. We manually identified outlier SNPs that may be driving the observed 1283 
directional pleiotropy and we repeated the analyses (IVW and MR-Egger) after excluding the 1284 
variants exhibiting directional pleiotropy. 1285 
The selection of SNPs for the vascular GRS is based on literature (Pubmed) search and the 1286 
GWAS catalog (http://www.ebi.ac.uk/gwas/) identifying studies that performed GWAS of the 1287 
various risk factors. The latest and largest GWAS of each risk factor was selected and the 1288 
associated variant details were retrieved. For the GRS analysis only independent variants 1289 
(r2<0.01, based on 1000G EUR panel) were used for the analysis (Supplementary Table 27). 1290 
Risk variant selection for BP traits (SBP, DBP, MAP and PP) was further extended to studies 1291 
with gene-centric chips. We used beta-coefficients extracted from the summary statistics of 1292 
the International Consortium of BP GWAS79,80 as weights for this GRS analysis. A p-value of 1293 
< 5.6 x 10-3 correcting for 9 independent phenotypes was considered significant. The number 1294 
of independent vascular phenotypes, taking into account correlation between the phenotypes 1295 
considered, was estimated based on individual level data from the 3C study using the online 1296 
tool matSpDlite (http://neurogenetics.qimrberghofer.edu.au/matSpDlite/). 1297 
 1298 
Shared genetic contribution to stroke and related vascular traits at the whole genome level 1299 
We used LD score regression to estimate the genetic correlation between stroke and related 1300 
vascular traits.33,34 We conducted analyses on the European and East-Asian stroke GWAS 1301 
summary statistics only. Summary statistics from the GWAS meta-analyses for vascular risk 1302 
factors and intermediate or related vascular phenotypes (BP, blood lipids, T2D, cIMT, cPL, 1303 
AF, VTE, CAD, WMH) were acquired from the respective consortia, as detailed in 1304 
Supplementary Table 12. For LD-score regression in East-Asians we further received access 1305 
to unpublished summary statistics of GWAS for blood lipids conducted in BioBank Japan, as 1306 
described in the Supplementary Note. For each trait, we filtered the summary statistics to the 1307 
subset of HapMap 3 SNPs to reduce the potential for bias due to poor imputation quality. 1308 
Analyses were performed separately using summary statistics from the European and East 1309 
Asian-specific meta-analysis. We used the European or East-Asian LD score files calculated 1310 
from the 1000G reference panel and provided by the developers. A p-value of < 5.6 x 10-3 1311 
correcting for 9 independent phenotypes was considered significant. All analyses were 1312 
performed using the ldsc package (https://github.com/bulik/ldsc). 1313 
 1314 
Global epigenetic patterns at the 32 stroke risk loci 1315 
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We used the epigwas tool35 to test for cell-specific enrichment in chromatin marks that were 1316 
previously shown to be phenotypically cell-type specific in ENCODE and/or RoadMap 1317 
epigenome data (H3K4me1, H3K4me3, H3K9ac)35, leveraging the recent release of 1318 
ENCODE/RoadMap epigenome data from 127 tissue types.36 Histone ChIP-seq data for 1319 
narrow contiguous regions of enrichment was used to calculate the enrichment score (height 1320 
of the nearest tall peak / distance to the peak) for the lead variant and proxies (r2 > 0.8 in the 1321 
1000G cosmopolitan panel). Significance was estimated by examining the relative proximity 1322 
and specificity of the test SNP set with 10,000 sets (permutation) of matched background. In 1323 
addition, Bonferroni correction for the number of chromatin marks tested was applied. 1324 
 1325 
Pathway Analyses 1326 
To identify pathways overrepresented in the stroke association results we used Data-driven 1327 
Expression-prioritized Integration for Complex Traits (DEPICT37), Ingenuity Pathway 1328 
Analysis (IPA, https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/), 1329 
and VEGAS2Pathway.39 DEPICT version 1 rel 194, was used to identify biological pathways, 1330 
tissues, and cell types enriched among suggestive associations (log10[BF] > 5) for any stroke 1331 
and stroke subtypes in the MANTRA transethnic GWAS. Results are presented for the 1332 
MANTRA transethnic analysis.  We deemed DEPICT pathways with an FDR <0.05 as 1333 
statistically significant.  1334 
IPA Pathway analysis was conducted using an extended gene list. The latter comprised genes 1335 
lying in the boundaries defined by r2 > 0.5 with the lead SNP in Europeans or East-Asians, or 1336 
being located +50kB from the lead SNP, for all suggestive loci reaching p < 1.0 x 10-5 or 1337 
log10(BF) > 5, and consisted of 214 genes (Supplementary Table 25). This gene list was 1338 
taken as an input for IPA, using only findings from human and experimentally verified 1339 
results. Otherwise, standard parameters were used for the analysis. We corrected canonical 1340 
pathway p-value with the Benjamini-Hochberg method and deemed an FDR < 0.05 as 1341 
significant.  1342 
We performed gene-wide gene-set enrichment analysis using the VEGAS2Pathway 1343 
approach39 to test which Biosystem terms38 are enriched with VEGAS2 derived gene 1344 
association p-values for stroke subtypes. VEGAS2Pathway performs a competitive gene-set 1345 
enrichment test, while accounting for gene-density in LD blocks (or correlated association p-1346 
values of neighbouring genes), SNP density and pathway size using a resampling strategy.  1347 
For individual stroke subtypes we performed separate ancestry-specific gene-set enrichment 1348 
analysis. Next, we combined the gene-set enrichment association p-values across ancestry 1349 
using Stouffer’s method for sample size weighted combination of p-values. For each stroke 1350 
subtype we tested association of 9,981 Biosystem genesets terms. 1351 
 1352 
Fine-mapping derived from credible SNP set analyses 1353 
We implemented the method of Maller et al.81, converting our ancestry-specific meta-analysis 1354 
p-values to Bayes factors using Wakefield's approximation40, in all stroke phenotypes in the 1355 
EUR only, EAS only and AFR only analysis. We used all SNPs in LD with the lead SNP (r2 > 1356 
0.1, ancestry-specific). The Bayes factors were then used to calculate posterior probabilities, 1357 
based on the assumption of a single causal SNP in each region. For all regions, we 1358 
constructed 95% credible sets of potentially causal SNPs. 1359 
 1360 
Investigation of eQTLs, pQTLs, meQTLs and regulatory marks in different tissues 1361 
The following datasets, covering a large variety of tissue and cell types were interrogated for 1362 
eQTLs, pQTLs, and meQTLs:  1363 
- The Genotype-Tissue Expression (GTEx-V6) project data providing significant eQTL 1364 
information from 44 post-mortem tissues (449 individuals) 1365 
31 
 
(http://biorxiv.org/content/early/2016/09/09/074450), significance is based on gene-1366 
specific p-value threshold that is permutation-adjusted for multiple SNPs per gene. 1367 
- The Genome-wide Repository of Associations between SNPs and Phenotypes build 2.0 1368 
(GRASP2),46,47 as well as a collected expression and epigenetic QTL database of >100 1369 
sources covering a wide range of cell and tissue types (Supplementary Note), using 1370 
p<5x10-6 as a significance threshold for association with expression of a transcript in the 1371 
original study  1372 
- The Human Genetic Variation Database (HGVD)48 providing eQTL information from 1373 
peripheral blood cells in a Japanese population (N=1,208) with significance defined by a 1374 
FDR < 5%. 1375 
- The Biobank-based Integrative Omics Studies (BIOS) providing eQTLs from peripheral 1376 
blood RNA-seq data in 2,116 unrelated individuals49, significance is defined by FDR < 1377 
5%. 1378 
- A subset of the Blueprint epigenome project50 with eQTL, meQTL and histone 1379 
modification data (H3K4me1 and H3K27ac) in CD14+ monocytes, CD16+ neutrophils 1380 
and CD4+ naïve T cells from 197 individuals; these were mapped using the classical QTL 1381 
association test, allele-specific expression (ASE) test and the combined haplotype test, 1382 
with significance defined by FDR < 5%.  1383 
- The Stockholm-Tartu Atherosclerosis Reverse Networks Engineering Task study 1384 
(STARNET)51, providing eQTL data from vascular and metabolic tissues in 600 CAD 1385 
patients, with association p-values corrected by Benjamini-Hochberg (p < 0.05) 1386 
- The aortic endothelial cells study52 providing eQTL data from human aortic endothelial 1387 
cells in 147 individuals, with Bonferroni multiple testing correction for the number of 1388 
independent SNPs (p < 1.0 x 10-4)  1389 
- The ARIC cohort53 providing meQTL information from peripheral blood in 794 of 1390 
European ancestry and 784 of African-American ancestry individuals from, with multiple 1391 
testing correction for the number of unique CpG probes in the look-up. 1392 
- The Cooperative health Research in the region of Augsburg (KORA) cohort with pQTL 1393 
information from the human blood plasma proteome54 measuring 1,124 proteins on the 1394 
SomaSCAN platform in 1,000 participants. Significance for each association was set at p < 1395 
5.0 x 10-8. 1396 
In each of these datasets we report the most significant cis QTL, meQTL, or pQTL surpassing 1397 
a study-specific predefined significance level or FDR, considering only QTLs in LD with the 1398 
lead stroke SNP at an r2>0.8 (in 1000G, as well as queries of multiple builds of SNAP82 and 1399 
SNiPA83), suggesting high concordance. Results are presented grouped per tissue or cell type 1400 
(Supplementary Table 23), or per stroke risk locus (Supplementary Table 22). In addition, 1401 
we also systematically report the association of the top QTL with stroke risk, and of the lead 1402 
stroke risk variant with the corresponding transcript expression, methylation level, or protein 1403 
level (Supplementary Table 23).    1404 
In addition we used a subset of the Blueprint epigenome project in CD14+ monocytes, 1405 
CD16+ neutrophils and CD4+ naïve T cells from 197 individuals50 and Haploreg V484 to 1406 
annotate the lead variants and proxies for enrichment in specific histone modification marks 1407 
for the chromatin state, based on ChIP-Seq data from multiple cell/tissue types from 1408 
ENCODE (Encyclopedia of DNA Elements)85 and NIH RoadMap epigenome.36 Results for 1409 
each of the lead SNPs and its proxies are displayed in detail in Supplementary Table 22.  1410 
 1411 
Integration of association statistics and in silico functional information using RiVIERA-1412 
beta 1413 
To identify the most plausible causal variants and genes we used the RiVIERA software59, 1414 
which jointly models the summary association statistics and the corresponding epigenetic 1415 
regulatory information in a Bayesian framework to estimate the PPA. The empirical prior of a 1416 
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variant to be associated with the respective trait through regulatory features was generated 1417 
using the 848 tissue-specific epigenomic data in 7 chromatin (H3K4me1, H3K4me3, 1418 
H3K36me3, H3K27me3, H3K9me3, H3K27ac, H3K9ac) and DNA accessibility (DNase I) 1419 
marks from the ENCODE/RoadMap epigenome data. Binary epigenomic annotation matrices 1420 
of a variant overlapping the narrow peaks were generated. For inferring the causal region, 1421 
RiVIERA-beta performs a repeated (n=1,000) random sampling step per locus, with the step 1422 
size set to 1.0 x 10-4. Iteration is performed until the convergence (acceptance rate of > 60 %) 1423 
is achieved, which is critical for the accurate estimation of PPA. We generated 95% credible 1424 
sets in each region based on the PPA. Regional plots were generated using the association 1425 
statistics and the PPA. Epigenetic enrichment over a fixed window size (50bp) per tissue 1426 
group was generated, by taking cumulative sum of empirical prior weighted global epigenetic 1427 
enrichment. Tissues were grouped into 19 groups as defined in the NIH RoadMap epigenome 1428 
project. 1429 
 1430 
Scoring method 1431 
In an attempt to prioritize the most likely biological candidate genes, we integrated functional 1432 
and biological information into an empirical score for each of the genes residing in the 32 1433 
genome-wide significant loci. These comprised 149 genes within the region defined by an r2 > 1434 
0.5 in any of the 1000G European or East-Asian populations or physical distances of ±50 kb 1435 
from the lead SNP of the respective locus (Supplementary Table 25). A score of 1 was 1436 
assigned for being the nearest gene to the lead SNP, for harboring a missense variant, for 1437 
harboring histone marks H3K4me3, H3K9ac and H3K4me1 peaks in cells types that showed 1438 
significant enrichment in epigwas analysis, and functioning as an eGene for an eQTL, 1439 
meQTL, or pQTL (1 point for each) in at least one study and one tissue type. In addition, a 1440 
score of 1 was assigned for each stroke phenotype showing evidence of being a drug target 1441 
gene in the DrugBank database (ATC-C and ATC-B01) and the Therapeutic Target Database 1442 
(Supplementary Table 25), and for overlap with biological pathways in DEPICT, IPA, or 1443 
VEGAS2 (Supplementary Tables 18 to 20). 1444 
 1445 
 1446 
Drug-Target gene enrichment analysis 1447 
For each locus containing a variant with log10(BF) > 5 in the MANTRA analysis, we 1448 
annotated the genes by considering LD structures (r2 > 0.5 in any of 1KG EUR or ASN 1449 
populations) or physical distances (±50 kbp ) from the lead SNP of the respective locus. Drug 1450 
target genes were extracted from the DrugBank database86 (considering those registered as 1451 
pharmacological "active targets; https://www.drugbank.ca/) and Therapeutic Target 1452 
Database87 (TTD; http://bidd.nus.edu.sg/group/cjttd/TTD_HOME.asp) resulting in a list of 1453 
1,123 genes (and corresponding proteins) annotated to currently approved drugs indicated for 1454 
any diseases (Supplementary Table 25). Drugs indicated for antithrombotic therapy (n = 69) 1455 
and cardiovascular diseases (n = 324) were curated from Anatomical Therapeutic Chemical 1456 
(ATC) codes (Supplementary Table 25). Enrichment of overlap between stroke-associated 1457 
genes with drug targets for antithrombotic therapy and cardiovascular diseases were assessed 1458 
by Fisher’s exact test. 1459 
 1460 
Data availability 1461 
The datasets generated and/or analyzed during the current study are available from the corresponding authors 1462 
upon reasonable request. 1463 
 1464 
1465 
33 
 
METHODS-ONLY REFERENCES  1466 
 1467 
72. Winkler, T.W. et al. Quality control and conduct of genome-wide association meta-1468 
analyses. Nat Protoc 9, 1192-212 (2014). 1469 
73. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of 1470 
genomewide association scans. Bioinformatics 26, 2190-1 (2010). 1471 
74. So, H.C., Gui, A.H., Cherny, S.S. & Sham, P.C. Evaluating the heritability explained 1472 
by known susceptibility variants: a survey of ten complex diseases. Genet Epidemiol 1473 
35, 310-7 (2011). 1474 
75. Feigin, V.L., Lawes, C.M., Bennett, D.A. & Anderson, C.S. Stroke epidemiology: a 1475 
review of population-based studies of incidence, prevalence, and case-fatality in the 1476 
late 20th century. Lancet Neurol 2, 43-53 (2003). 1477 
76. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary 1478 
statistics identifies additional variants influencing complex traits. Nat Genet 44, 369-1479 
75, S1-3 (2012). 1480 
77. Liu, J.Z. et al. A versatile gene-based test for genome-wide association studies. Am J 1481 
Hum Genet 87, 139-45 (2010). 1482 
78. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid 1483 
instruments: effect estimation and bias detection through Egger regression. Int J 1484 
Epidemiol 44, 512-25 (2015). 1485 
79. International Consortium for Blood Pressure Genome-Wide Association Studies et al. 1486 
Genetic variants in novel pathways influence blood pressure and cardiovascular 1487 
disease risk. Nature 478, 103-9 (2011). 1488 
80. Wain, L.V. et al. Genome-wide association study identifies six new loci influencing 1489 
pulse pressure and mean arterial pressure. Nat Genet 43, 1005-11 (2011). 1490 
81. Wellcome Trust Case Control Consortium et al. Bayesian refinement of association 1491 
signals for 14 loci in 3 common diseases. Nat Genet 44, 1294-301 (2012). 1492 
82. Johnson, A.D. et al. SNAP: a web-based tool for identification and annotation of 1493 
proxy SNPs using HapMap. Bioinformatics 24, 2938-9 (2008). 1494 
83. Arnold, M., Raffler, J., Pfeufer, A., Suhre, K. & Kastenmuller, G. SNiPA: an 1495 
interactive, genetic variant-centered annotation browser. Bioinformatics 31, 1334-6 1496 
(2015). 1497 
84. Ward, L.D. & Kellis, M. HaploReg v4: systematic mining of putative causal variants, 1498 
cell types, regulators and target genes for human complex traits and disease. Nucleic 1499 
Acids Res 44, D877-81 (2016). 1500 
85. Encode Project Consortium. An integrated encyclopedia of DNA elements in the 1501 
human genome. Nature 489, 57-74 (2012). 1502 
86. Wishart, D.S. et al. DrugBank: a comprehensive resource for in silico drug discovery 1503 
and exploration. Nucleic Acids Res 34, D668-72 (2006). 1504 
87. Yang, H. et al. Therapeutic target database update 2016: enriched resource for bench 1505 
to clinical drug target and targeted pathway information. Nucleic Acids Res 44, 1506 
D1069-74 (2016). 1507 
88. Kato, N. et al. Meta-analysis of genome-wide association studies identifies common 1508 
variants associated with blood pressure variation in east Asians. Nat Genet 43, 531-8 1509 
(2011). 1510 
89. Surendran, P. et al. Trans-ancestry meta-analyses identify rare and common variants 1511 
associated with blood pressure and hypertension. Nat Genet 48, 1151-61 (2016). 1512 
 1513 
FE meta-analysis: 
P< 5x10-8; Phet < 5x10
-8
AFR
5 studies
5,541 / 15,154
EUR
17 studies
40,585 / 406,111
EAS
2 studies
17,369 / 28,195
SAS
3 studies
2,437 / 6,707
ASN
1 study
365 / 333
LAT
1 study
865 / 692
Central QC: -5 < β < 5; Imp > 0.5; MAF > 0.01; EAC/study > 10 
Trans-ethnic meta-analysis
22 new stroke-associated loci identified
MANTRA: 
log10(BF) > 6 & PPhet < 0.95
Ancestry-specific FE meta-analysis*
AS, AIS, LAS, CES, SVS
29 studies = 67,162 cases / 454,450 controls
~8M variants imputed using 1000G or UK10K/HRC
Figure 1
C
A
SZ
1
W
N
T2
B
TS
PA
N
2
PM
F1
-S
EM
A
4A
R
G
S7
KC
NK
3
TM
4S
F4
-T
M
4S
F1
PI
TX
2
A
N
K
2
ED
N
R
A
FG
A
LO
C1
00
50
58
41
N
K
X2
-5
FO
XF
2
SL
C
22
A
7-
ZN
F3
18
H
D
A
C
9-
TW
IS
T1
C
D
K
6
C
hr
9p
21
LI
N
C
01
49
2
A
B
O
SH
3P
XD
2A
M
M
P1
2
PD
E3
A
SH
2B
3
TB
X3
LR
C
H
1
FU
R
IN
-F
ES
ZF
H
X3
ZC
C
H
C
14
PR
PF
8
IL
F3
-S
LC
44
A
2
SM
A
R
C
A
4-
LD
LR
 
         
      
 
 
 
   
 
  
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Genome-wide significance in transethnic meta-analysis
Genome-wide significance in Europeans-only meta-analysis
Genome-wide significance in both the transethnic meta-analysis and Europeans-only meta-analysis
 
 
  
 
 
Any stroke
Any ischemic stroke
Large artery stroke
Cardioembolic stroke
Small vessel stroke
ZC
C
H
C
14
SM
A
R
C
A
4-
LD
LR
LR
C
H
1SH
2B
3
TB
X3
SH
3P
XD
2A
C
hr
9p
21
H
D
A
C
9-
TW
IS
T1
C
D
K
6
PI
TX
2
FG
A
LO
C1
00
50
58
41
FO
XF
2
SL
C
22
A
7-
ZN
F3
18
C
A
SZ
1
W
N
T2
B
PM
F1
-S
EM
A
4A
KC
NK
3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19202122
0
lo
g1
0(
B
ay
es
 F
ac
to
r)
2
4
6
8
10
12
14
Figure 2
CASZ1
WNT2B
TSPAN2
PMF1-SEMA4A
RGS7
KCNK3
TM4SF4-TM4SF1
PITX2
ANK2
EDNRA
FGA
LOC100505841
NKX2-5
FOXF2
SLC22A7-ZNF318 
HDAC9-TWIST1
CDK6
Chr9p21
LINC01492
ABO
SH3PXD2A
MMP12
PDE3A
SH2B3
TBX3
LRCH1
FURIN-FES
ZFHX3
ZCCHC14
PRPF8
ILF3-SLC44A2
SMARCA4-LDLR
Carotid plaque
Carotid IMT
Systolic BP
Diastolic BP
White matter
hyperintensities
on brain MRI
Atrial fibrillation
Coronary
artery disease
LDL levels
HDL levels
Venous
Thromboembolism
P-value
<1.30 x 10 -04
<5 x 10 -08
Related 
vascular 
trait
Stroke 
Subtype
(A) (B)
LAS
LAS
LAS
CES
CES
LAS
LAS
CES
CES
SVS
Locus
Carotid plaque 
or IMT
Blood 
pressure
White matter
hyperintensities
on brain MRI
Atrial 
fibrillation
CAD
Lipid levels
Venous
Thrombo-
embolism
PMF1-
SEMA4A
 LOC100505841
SH3PXD2A
NKX2-5†
PITX2†
FOXF2
PDE3A
SLC22A7-
ZNF318
WNT2B
LRCH1
ANK2
TM4SF4-TM4SF1 PRPF8
MMP12
LINC01492
CASZ1
KCNK3
TBX3
FURIN-
FES
HDAC9-
TWIST1
Chr9p21
SH2B3
SMARCA4-
LDLR
ABO
FGA
RGS7†
TSPAN2ZCCHC14*
CDK6
EDNRA
EDNRA
ZFHX3†
ILF3-
SLC44A2
Stroke
Figure 3
5.6E-3 
1E-5
1E-10
1E-20
p-value
β/R(g)
n.s.
1.0
-1.0
0.0
AS
AIS
LAS
CES
SVS
AS
AIS
LAS
CES
SVS
LD
 S
co
re
 R
eg
re
ss
io
n
w
ei
gh
te
d 
G
R
S
VTE DBP SBP MAP PP HTN HDL LDL TGL T2D CAD
Figure 4
rs6825454 
rs56393506 
rs7304841 
FGA 
PLG 
PDE3A Cilostazol 
Streptokinase 
Melagatran 
Alteplase 
 Tenecteplase 
Anistreplase 
Reteplase 
Stroke risk 
SNPs 
Biological genes 
within the locus 
Targeted 
drugs 
Indication 
  
Antithrombotic 
therapy 
Figure 5
